Literature DB >> 30526328

Disease course patterns in systemic lupus erythematosus.

K Tselios1, D D Gladman1, Z Touma1, J Su1, N Anderson1, M B Urowitz1.   

Abstract

BACKGROUND: Disease activity in systemic lupus erythematosus follows three different courses: long quiescent, relapsing remitting and persistently active. However, the patterns of disease course since diagnosis are not known. This study aimed to assess the prevalence and characteristics of such patterns over 10 years. PATIENTS AND METHODS: The inception cohort of the Toronto Lupus Clinic (≥10 year follow up, between visit interval ≤18 months) was investigated. Prolonged remission was defined as a clinical Systemic Lupus Erythematosus Disease Activity Index 2000 = 0 achieved within 5 years of enrolment and maintained for ≥10 years. The relapsing-remitting pattern was defined based on ≥2 remission periods (clinical Systemic Lupus Erythematosus Disease Activity Index 2000 = 0 for two consecutive visits). Patients with no remission were categorized as persistently active. Groups were compared for baseline characteristics, cumulative damage, flare rate, mortality and certain co-morbidities.
RESULTS: Of 267 patients, 27 (10.1%) achieved prolonged remission, 180 (67.4%) relapsing-remitting and 25 (9.4%) persistently active. In total, 35 (13.1%) had only one remission period (hybrid). At enrollment, there were no differences regarding clinical and immunological variables. At 10 years, persistently active patients had accumulated significantly more damage than the prolonged remission and relapsing-remitting patients. Being of Black race and higher adjusted mean Systemic Lupus Erythematosus Disease Activity Index 2000 over the first 2 years were associated with a more severe disease course. Relapsing-remitting and persistently active patients had an increased flare rate and accrued more osteoporosis, osteonecrosis and cardiovascular events.
CONCLUSIONS: Approximately 70% of systemic lupus erythematosus patients followed a relapsing-remitting course, whereas 10% displayed prolonged remission and another 10% a persistently active course. Early response to treatment was associated with a less severe course and better prognosis.

Entities:  

Keywords:  Patterns of disease course; prognosis; systemic lupus erythematosus

Mesh:

Year:  2018        PMID: 30526328     DOI: 10.1177/0961203318817132

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  12 in total

Review 1.  Antimalarials - old drugs are new again.

Authors:  Anna Woźniacka
Journal:  Postepy Dermatol Alergol       Date:  2021-08-11       Impact factor: 1.664

2.  Measurement of circulating CD21-CD27- B lymphocytes in SLE patients is associated with disease activity independently of conventional serological biomarkers.

Authors:  Alice Horisberger; Morgane Humbel; Natalia Fluder; Florence Bellanger; Craig Fenwick; Camillo Ribi; Denis Comte
Journal:  Sci Rep       Date:  2022-06-02       Impact factor: 4.996

3.  Risk factors of disease flares in a Chinese lupus cohort with low-grade disease activity.

Authors:  Fangfang Sun; Liling Zhao; Haiting Wang; Danting Zhang; Jie Chen; Xiaodong Wang; Ting Li; Shuang Ye
Journal:  Lupus Sci Med       Date:  2022-05

Review 4.  Clinical disease activity and flare in SLE: Current concepts and novel biomarkers.

Authors:  Aikaterini Thanou; Eldon Jupe; Mohan Purushothaman; Timothy B Niewold; Melissa E Munroe
Journal:  J Autoimmun       Date:  2021-02-22       Impact factor: 7.094

5.  Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease.

Authors:  Dionysis S Nikolopoulos; Myrto Kostopoulou; Dimitrios T Boumpas; Antonis Fanouriakis; Antigoni Pieta; Sofia Flouda; Katerina Chavatza; Aggelos Banos; John Boletis; Pelagia Katsimbri
Journal:  Lupus Sci Med       Date:  2020-06

6.  The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus.

Authors:  Lloyd Mai; Arundip Asaduzzaman; Babak Noamani; Paul R Fortin; Dafna D Gladman; Zahi Touma; Murray B Urowitz; Joan Wither
Journal:  Arthritis Res Ther       Date:  2021-01-16       Impact factor: 5.156

Review 7.  Epstein-Barr Virus and Systemic Autoimmune Diseases.

Authors:  Gunnar Houen; Nicole Hartwig Trier
Journal:  Front Immunol       Date:  2021-01-07       Impact factor: 7.561

8.  Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.

Authors:  Manuel Francisco Ugarte-Gil; Anselm Mak; Joanna Leong; Bhushan Dharmadhikari; Nien Yee Kow; Cristina Reátegui-Sokolova; Claudia Elera-Fitzcarrald; Cinthia Aranow; Laurent Arnaud; Anca D Askanase; Sang-Cheol Bae; Sasha Bernatsky; Ian N Bruce; Jill Buyon; Nathalie Costedoat-Chalumeau; Mary Ann Dooley; Paul R Fortin; Ellen M Ginzler; Dafna D Gladman; John Hanly; Murat Inanc; David Isenberg; Soren Jacobsen; Judith A James; Andreas Jönsen; Kenneth Kalunian; Diane L Kamen; Sung Sam Lim; Eric Morand; Marta Mosca; Christine Peschken; Bernardo A Pons-Estel; Anisur Rahman; Rosalind Ramsey-Goldman; John Reynolds; Juanita Romero-Diaz; Guillermo Ruiz-Irastorza; Jorge Sánchez-Guerrero; Elisabet Svenungsson; Murray Urowitz; Evelyne Vinet; Ronald F van Vollenhoven; Alexandre Voskuyl; Daniel J Wallace; Michelle A Petri; Susan Manzi; Ann Elaine Clarke; Mike Cheung; Vernon Farewell; Graciela S Alarcon
Journal:  Lupus Sci Med       Date:  2021-12

9.  Treatment Patterns and Clinical Characteristics of Patients with Systemic Lupus Erythematosus and Musculoskeletal Symptoms: A Retrospective, Observational Study.

Authors:  Natalia Bello; Julie A Birt; Jennifer Workman; Xian Zhou; Jorge A Ross-Terres; Michelle Petri
Journal:  Adv Ther       Date:  2022-05-09       Impact factor: 4.070

Review 10.  Potential for Antigen-Specific Tolerizing Immunotherapy in Systematic Lupus Erythematosus.

Authors:  Sean Robinson; Ranjeny Thomas
Journal:  Front Immunol       Date:  2021-07-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.